The buying is modest in scale and comes from asset managers rather than activist or event-driven funds. Monitor upcoming earnings and pipeline updates for catalysts that could drive broader institutional re-rating.
NVO drugs
NVO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $40.30entry
- T+1 · 11d ago +0.02%α −0.29% · $40.31
- T+5 · 5d ago +0.87%α −2.42% · $40.65
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Three institutional investors added or initiated positions in Novo Nordisk during Q3 2026, with net buying of $22.4M, while one trimmed. The cluster is small in dollar terms relative to the company's $178B market cap and lacks insider corroboration, limiting its signal strength.
Key Financial Metrics
Institutional Positions
Net institutional flow: $22.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Citigroup | ADD | +41.7% | $54.0M | $5.8M |
| Keybank National Association | ADD | +28.8% | $2.8M | $51.0K |
| Imc-Chicago | NEW | +100% | $16.6M | $16.6M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Banque Pictet & Cie | TRIM | -61.5% | $4.1M | -$2.8M |
Key Facts
- Three institutions (Citigroup, Keybank, IMC-Chicago) accumulated $22.4M in net new positions during Q3 2026
- Citigroup added 41.7% to its position, increasing value from $48.2M to $54.0M
- IMC-Chicago initiated a new $16.6M position
- Banque Pictet trimmed 61.5% of its holding, reducing value by $2.8M
- No open-market insider buying was detected in the same window (confluence score 23/100)
Financial Impact
Net institutional buying of $22.4M, representing about 0.013% of Novo Nordisk's $178B market cap
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- No insider buying to corroborate the institutional signal
- Small dollar amounts relative to market cap limit the signal's materiality
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-NVO-2026-Q3 |
Track record
43 reports on NVO
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 settles Dec 15
- Nov 9, 20267d ago 6-K Neutral 2/10 Entry $41.38 settles Dec 8
- Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Viewing Entry $40.30 settles Dec 4
- Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 settles Dec 4
- Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 settles Dec 3
- Nov 3, 202613d ago 6-K Neutral 2/10 Entry $40.19 settles Dec 2
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 settles Nov 23
- Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 settles Nov 24
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers